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cular arrhythmias (VA), heart failure (Killip class>1) and 30-day mortality
were collected.
 
Results:
 
 Among the 1541 patients included in the study, 693 patients
presented PIA. Baseline clinical characteristics were similar for the 2
groups. There was no significant difference for the GRACE risk score
(p=0.942). However, PIA was associated with a lower creatine kinase
peak, as a reflect of infarct size (231(109-520) vs. 322(148-844) IU/L,
p<0.001) and a lower rate of patients with a troponin peak >100 ULN
(31% vs. 39%, p<0.001) when compared with the group without PIA.
Patients with PIA were admitted with markedly less pre-hospital RCA
(0.6% vs. 3.4%, p<0.001) and developed fewer VA (1.6% vs. 4.0%,
p=0.008) and heart failure (18.2% vs. 22.6%, p=0.037) during the hospital
stay. There was a trend toward a decrease in 30-day death in patients with
PIA (4.3% vs 6.1%, p=0.146).
 
Conclusion:
 
 From this large contemporary observational study, PIA is
observed in almost 50% of patients admitted for a first NSTEMI. In such
patients, PIA is associated with less pre-hospital RCA, and decreased in-hos-
pital VA and heart failure. These findings suggest that identifying lack of PIA
in patients admitted for a NSTEMI could help for early risk stratification, in
particular for ventricular arrhythmias.
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Context:
 
 Assessment of bleeding risk is often crucial for making decisions
regarding chronic use of antithrombotics.
 
Objective:
 
 To develop a risk score to quantify bleeding risk in outpa-
tients. Design, Setting, and Participants We studied patients enrolled in the
Reduction of Atherothrombosis for Continued Health (REACH) Registry,
a cohort of 68 236 patients with or at risk of atherothrombosis. The out-
come of interest was serious bleeding (non-fatal hemorrhagic stroke or
bleeding requiring hospitalization and transfusion) over 2 years. Risk fac-
tors for bleeding were assessed using modified regression analysis. Mul-
tiple potential scoring systems based on the least complex models were
constructed. Competing scores were compared on their discriminative abi-
lity via logistic regression. The score was validated externally using the
CHARISMA population.
 
Results:
 
 From a final cohort of 56 616 patients, 804 (1.42%) experienced
serious bleeding between baseline and 2 years. A nine-item bleeding risk
score, ranging from 0 to 23 points, was constructed including age, peripheral
arterial disease, congestive heart failure, diabetes, hypertension, smoking, anti-
platelets, oral anticoagulants, and hypercholesterolemia. Observed incidence
of bleeding at 2 years was: 0.46% in patients with a score 
 
≤
 
6; 0.95% for scores
7-8; 1.25% for scores 9-10; and 2.76% for scores 
 
≥
 
11. The score’s discrimi-
native performance was consistent in CHARISMA and REACH (c-statistics
0.63 and 0.68, respectively); calibration in the CHARISMA population was
very good (modified Hosmer-Lemeshow 
 
χ
 
2
 
=4.74; 
 
P
 
=.69).
 
Conclusions:
 
 Bleeding risk increases dramatically with a score >10. This
score can assist clinicians in predicting the risk of serious bleeding and making
decisions on antithrombotic therapy in outpatients with atherothrombosis.
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Aim:
 
 The CHADS
 
2
 
 score is a reliable, easy-to-use, and popular bedside
score to assess the risk of stroke in patients with atrial fibrillation (AF). The
items of the score are all key determinants of prognosis in vascular patients.
We compare CHADS
 
2
 
 to established scores (the Framingham score and the
European SCORE) for their ability to predict adverse cardiovascular outcome
in atherothrombotic patients without AF.
 
Methods: 
 
Individual risk scores were calculated in 18,888 stable athe-
rothrombotic patients without AF included in the European REACH registry in
18 European countries between 2003 and 2004. Each scheme was divided into
low, intermediate and high predicted risk categories and applied to the cohort.
MACCE (CV Death, MI or Stroke) were recorded at 2 years follow-up.
 
Results:
 
 Two hundred six deaths and 987 MACCE occurred during 37776
patients-years follow up. According to CHADS
 
2
 
 score, 38.2% (7234 patients with
CHADS
 
2
 
=0-1) had low, 48.2% (9101 patients with CHADS
 
2
 
=2-3) had interme-
diate and 13.5% had high predicted CV risk (2553 patients with CHADS
 
2
 
=4-6)
(figure A). The proportion of individual assigned to individual risk categories
varied widely across schemes (low risk ranged from 26.6 % to 88.6%, high risk
from 1.5% to 25.0%). Although the risk scores had only poor discriminating abi-
lity, CHADS
 
2
 
 had the higher c-statistics of 0.613 (figure B). In multivariable
logistic regression, the CHADS
 
2
 
 score (high vs low risk) remains an independent
predictor of MACCE even after adjustement to Framingham score (OR 2.78 [95%
CI 2.3 to 3.3] ) or european SCORE (OR 2.94 [95% CI 2.45 to 3.5] ).
 
Conclusions:
 
 The CHADS
 
2
 
, a reliable, easy-to-use, bedside score, appears
to predict more accurately, adverse cardiovascular outcome in atherothrom-
botic patients without atrial fibrillation, than established scores. But current
risk scheme have limited ability and better scores are needed.
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Objective:
 
 Recent findings reported intriguing relationships between obe-
sity and natriuretic peptides. In patients with acute myocardial infarction (MI),
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